Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Infect Dis ; 216(suppl_1): S57-S65, 2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28838171

RESUMO

The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) ("the switch") presented an unprecedented challenge to countries. In order to mitigate the risks associated with country-level delays in implementing the switch, the Global Polio Eradication Initiative provided catalytic financial support to specific countries for operational costs unique to the switch. Between November 2015 and February 2016, a total of approximately US$19.4 million in financial support was provided to 67 countries. On average, country budgets allocated 20% to human resources, 23% to trainings and meetings, 8% to communications and advocacy, 9% to logistics, 15% to monitoring, and 5% to waste management. All 67 funded countries successfully switched from tOPV to bOPV during April-May 2016. This funding provided target countries with the necessary catalytic support to facilitate the execution of the switch on an accelerated timeline, and the mechanism offers a model for similar support to future global health efforts, such as the eventual global withdrawal of bOPV.


Assuntos
Erradicação de Doenças/economia , Erradicação de Doenças/organização & administração , Apoio Financeiro , Saúde Global/economia , Poliomielite , Vacina Antipólio Oral/economia , Humanos , Poliomielite/economia , Poliomielite/prevenção & controle
2.
J Infect Dis ; 216(suppl_1): S9-S14, 2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28838174

RESUMO

The Immunization Systems Management Group (IMG) was established to coordinate and oversee objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018, namely, (1) introduction of ≥1 dose of inactivated poliovirus vaccine in all 126 countries using oral poliovirus vaccine (OPV) only as of 2012, (2) full withdrawal of OPV, starting with the withdrawal of its type 2 component, and (3) using polio assets to strengthen immunization systems in 10 priority countries. The IMG's inclusive, transparent, and partnership-focused approach proved an effective means of leveraging the comparative and complementary strengths of each IMG member agency. This article outlines 10 key factors behind the IMG's success, providing a potential set of guiding principles for the establishment and implementation of other interagency collaborations and initiatives beyond the polio sphere.


Assuntos
Erradicação de Doenças , Saúde Global , Programas de Imunização , Poliomielite/prevenção & controle , Vacina Antipólio de Vírus Inativado/administração & dosagem , Vacina Antipólio Oral/administração & dosagem , Erradicação de Doenças/métodos , Erradicação de Doenças/organização & administração , Humanos , Programas de Imunização/métodos , Programas de Imunização/organização & administração , Objetivos Organizacionais
3.
J Infect Dis ; 216(suppl_1): S15-S23, 2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28838203

RESUMO

The Immunization Systems Management Group (IMG) was established as a time-limited entity, responsible for the management and coordination of Objective 2 of the Polio Eradication and Endgame Strategic Plan. This objective called for the introduction of at least 1 dose of inactivated polio vaccine (IPV) into the routine immunization programs of all countries using oral polio vaccine (OPV) only. Despite global vaccine shortages, which limited countries' abilities to access IPV in a timely manner, 105 of 126 countries using OPV only introduced IPV within a 2.5-year period, making it the fastest rollout of a new vaccine in history. This achievement can be attributed to several factors, including the coordination work of the IMG; high-level engagement and advocacy across partners; the strong foundations of the Expanded Programme on Immunization at all levels; Gavi, the Vaccine Alliance's vaccine introduction experiences and mechanisms; innovative approaches; and proactive communications. In many ways, the IMG's work on IPV introduction can serve as a model for other vaccine introductions, especially in an accelerated context.


Assuntos
Erradicação de Doenças , Saúde Global , Programas de Imunização , Poliomielite/prevenção & controle , Vacina Antipólio de Vírus Inativado , Erradicação de Doenças/métodos , Erradicação de Doenças/organização & administração , Humanos , Programas de Imunização/métodos , Programas de Imunização/organização & administração , Vacina Antipólio de Vírus Inativado/administração & dosagem , Vacina Antipólio de Vírus Inativado/uso terapêutico , Vacina Antipólio Oral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA